Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.

Chief Executive Officer Vladislav Sandler says: ‘I am excited by the decision of the United States Patent and Trademark Office to allow this patent application. This is a significant addition to the patent protection for CDX which remains one of our key product candidates for the future. This also solidifies our company’s position as a leader in the area of conditioning bone marrow transplants.’

Current stock price: 3.81 pence, up 12% in London on Friday morning

12-month change: up 64%

Copyright 2024 Alliance News Ltd. All Rights Reserved.